ZhenolutenЖенолутен
A peptide mixture described in the Russian report as calf or pig ovary extract. A translated edition gives a conflicting tissue source.
What the studies found
Comparison in people · 2019
Zhenoluten and Endoluten in women with reduced reproductive function
Study of multiple preparations
- Anti-Müllerian hormone at month four
- 1.16 ± 0.18 ng/mL with the combination versus 0.82 ± 0.24 with placebo. Baselines were 0.76 ± 0.13 and 0.74 ± 0.12 ng/mL, respectively.
- Estradiol at month four
- 616.24 ± 69.42 pmol/L with the combination versus 209.26 ± 12.64 with placebo.
- Pregnancies reported by months four through eight
- 180/214 (84%) with the combination versus 8/62 (13%) with placebo. The expanded report supplies no live-birth outcomes or detailed follow-up accounting.
In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.
Study notes · methods, sources and limitations
Participants or model 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
Design From 2013 to 2018, the Moscow center enrolled 276 women aged 34–38. The 214-person combination arm received oral Zhenoluten 20 mg each morning and Endoluten 10 mg every 72 hours for four months. The 62-person comparison received placebo. Neither group received hormone therapy.
Important limitations
- Group assignment and masking are unspecified. The report combines two products, so the effect of either alone is unknown. The pregnancy figures come from the authors’ expanded report. Live births, completeness of follow-up and maternal or neonatal safety data are unavailable. The conference methods and expanded report agree on every-72-hour Endoluten. A recommendation elsewhere in the conference reproduction gives a different schedule.
- The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The differences come from a comparison with unspecified allocation and masking.
9th European Congress of the International Association of Gerontology and Geriatrics, Gothenburg, 2019. Author material reproduced by Peptides. · Conference report and expanded author report
Comparison in people · 2011
Zhenoluten: institute clinical report (commercially hosted translation)
The report describes symptom and hormone changes during adjunctive treatment.
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Study notes · methods, sources and limitations
Participants or model 67 women: 39 with climacteric symptoms and 28 with early ovarian insufficiency; four comparison groups
Important limitations
- Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated. Group-specific denominators are unclear. The translated identity paragraph says triceps tissue despite an ovarian target; the original formulation must be checked. Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
Institute-attributed report, 2011; commercially hosted brochure pp. 34–35 · Institute report — commercial reproduction
About Zhenoluten
Identity / background source ↗
Research background
Zhenoluten is an ovarian tissue peptide preparation. A Medical Center report followed women with climacteric symptoms or early ovarian insufficiency. A separate 276-person report studied Zhenoluten together with Endoluten.
- Compound class
- Archival preparation lead
- Research collection
- Peptide bioregulation · editorial grouping
- Institutions in linked studies
- Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
- Source review
- Review dates and the material assessed are listed with each publication below.
Understanding the evidence
Human research
67 women: 39 with climacteric symptoms and 28 with early ovarian insufficiency; four comparison groups
Study methods
Small adjunctive comparison; signed original, allocation and reporting require verification
Independent replication
New citations are not automatically independent replication; shared programs and translated reports require cohort checks
Source access
New indexed primary abstracts and/or report reproductions linked; review depth shown per source
Safety evidence
Reported tolerability is not proof of safety; uncommon harms and long-term outcomes remain unresolved
Open a topic for the evidence assessment.
Findings by study
Tissue-preparation reports: comparisons, source limits and remaining gaps ↗
Comparison in people · 2019
Zhenoluten and Endoluten in women with reduced reproductive function
In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.
Study notes and original source
Zhenoluten and Endoluten in women with reduced reproductive function
Oral ovarian and pineal polypeptide combination · Conference report and expanded author report
D. A. Gorgiladze, R. N. Pinaev, V. A. Aleksandrov · 9th European Congress of the International Association of Gerontology and Geriatrics, Gothenburg, 2019. Author material reproduced by Peptides.
In the 276-person comparison, anti-Müllerian hormone was 1.16 versus 0.82 ng/mL after four months. The expanded report also lists 180/214 versus 8/62 pregnancies, with limited detail on allocation and follow-up.
Results and tables
Reported findings and study design
From 2013 to 2018, the Moscow center enrolled 276 women aged 34–38. The 214-person combination arm received oral Zhenoluten 20 mg each morning and Endoluten 10 mg every 72 hours for four months. The 62-person comparison received placebo. Neither group received hormone therapy.
Population or model 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Anti-Müllerian hormone at month four | 1.16 ± 0.18 ng/mL with the combination versus 0.82 ± 0.24 with placebo. Baselines were 0.76 ± 0.13 and 0.74 ± 0.12 ng/mL, respectively. | |
| Estradiol at month four | 616.24 ± 69.42 pmol/L with the combination versus 209.26 ± 12.64 with placebo. | |
| Pregnancies reported by months four through eight | 180/214 (84%) with the combination versus 8/62 (13%) with placebo. The expanded report supplies no live-birth outcomes or detailed follow-up accounting. |
The authors credit the St. Petersburg Institute of Bioregulation and Gerontology with developing both preparations. The study took place at the Centre for Revitalization and Health in Moscow. The differences come from a comparison with unspecified allocation and masking.
Source for these results ↗ · Reviewed 2026-11-16
- Population / setting
- 276 women aged 34–38: 214 received the peptide combination and 62 received placebo.
- Source reviewed
- Conference reproduction, PDF pages 21–22, and expanded author report, Tables 1–3. Both describe the same participants.
Study limitations
- Group assignment and masking are unspecified. The report combines two products, so the effect of either alone is unknown.
- The pregnancy figures come from the authors’ expanded report. Live births, completeness of follow-up and maternal or neonatal safety data are unavailable.
- The conference methods and expanded report agree on every-72-hour Endoluten. A recommendation elsewhere in the conference reproduction gives a different schedule.
Reviewed 2026-11-16.
Comparison in people · 2011
Zhenoluten: institute clinical report (commercially hosted translation)
The report describes symptom and hormone changes during adjunctive treatment.
Study notes and original source
Zhenoluten: institute clinical report (commercially hosted translation)
Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Tissue-derived mixture / named preparation · Institute report — commercial reproduction
Format: PDF · Reviewed: Report reproduction reviewed
St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute-attributed report, 2011; commercially hosted brochure pp. 34–35
The report describes symptom and hormone changes during adjunctive treatment.
- Population / setting
- 67 women: 39 with climacteric symptoms and 28 with early ovarian insufficiency; four comparison groups
- Source reviewed
- Brochure PDF pp. 34–35: methods/results text checked; selected population/table pages visually inspected. This is a provenance check, not authentication of the institute original.
Study limitations
- Commercial reproduction: signed original, protocol and translation accuracy have not been authenticated.
- Group-specific denominators are unclear. The translated identity paragraph says triceps tissue despite an ovarian target; the original formulation must be checked.
- Short follow-up and incomplete adverse-event methods do not establish safety; independent replication and present-day product equivalence remain unverified.
Reviewed 2026-10-05.
Related compound research
Follow shared publications or research classes. These links do not establish equivalent effects between compounds.
Research collection curated by @PepMariner · editorial standards. Send a source correction ↗
Browse bibliography & PDFs ↗